Couldn’t agree more, didn’t expect it to move the SP at all. Whilst it’s not a bad strategic move in terms of PR, it does not assist the caliber of the trials or the trial results, which solely will determine a positive re-rate. Just my opinion (as a holder and a believer of IHL).
I still have my corporate-related doubts of the potential Cannvalate/IHL structure concerning Dr Sud, but am happy with the progress thus far.
My gut suggests that long term IHL itself mightn’t be the play, but rather, Cannvalate will list on the ASX to raise funds to acquire IHL. Pure speculation, DYOR etc.
IHL Price at posting:
4.9¢ Sentiment: Hold Disclosure: Held
